Mutations_NNS in_IN the_DT N_NP Termini_NP of_IN Herpes_NP Simplex_NP Virus_NP Type_NP 1_CD and_CC 2_CD gDs_NNS Alter_NP Functional_NP Interactions_NP with_IN the_DT Entry/Fusion_NP Receptors_NP HVEM_NP ,_, Nectin-2_NP ,_, and_CC 3-O-Sulfated_JJ Heparan_NP Sulfate_NP but_CC Not_RB with_IN Nectin-1_NP Multiple_NP cell_NN surface_NN molecules_NNS (_( herpesvirus_NN entry_NN mediator_NN [_SYM HVEM_NP ]_SYM ,_, nectin-1_JJ ,_, nectin-2_JJ ,_, and_CC 3-O-sulfated_JJ heparan_JJ sulfate_NN )_) can_MD serve_VB as_IN entry_NN receptors_NNS for_IN herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) or_CC HSV-2_NP and_CC also_RB as_IN receptors_NNS for_IN virus-induced_JJ cell_NN fusion_NN ._SENT Viral_JJ glycoprotein_NN D_NP (_( gD_NN )_) is_VBZ the_DT ligand_NN for_IN these_DT receptors_NNS ._SENT A_DT previous_JJ study_NN showed_VBD that_IN HVEM_NP makes_VBZ contact_NN with_IN HSV-1_JJ gD_NNS at_IN regions_NNS within_IN amino_NN acids_NNS 7_CD to_TO 15_CD and_CC 24_CD to_TO 32_CD at_IN the_DT N_NP terminus_NN of_IN gD_NNS ._SENT In_IN the_DT present_JJ study_NN ,_, amino_NN acid_NN substitutions_NNS and_CC deletions_NNS were_VBD introduced_VBN into_IN the_DT N_NP termini_NNS of_IN HSV-1_NP and_CC HSV-2_NP gDs_NNS to_TO determine_VB the_DT effects_NNS on_IN interactions_NNS with_IN all_DT of_IN the_DT known_VBN human_NN and_CC mouse_NN entry/fusion_NN receptors_NNS ,_, including_VBG mouse_NN HVEM_NP ,_, for_IN which_WDT data_NNS on_IN HSV_NP entry_NN or_CC cell_NN fusion_NN were_VBD not_RB previously_RB reported_VBN ._SENT A_DT cell_NN fusion_NN assay_NN was_VBD used_VBN to_TO assess_VB functional_JJ activity_NN of_IN the_DT gD_JJ mutants_NNS with_IN each_DT entry/fusion_NN receptor_NN ._SENT Soluble_JJ gD:Fc_NN hybrids_NNS carrying_VBG each_DT mutation_NN were_VBD tested_VBN for_IN the_DT ability_NN to_TO bind_VB to_TO cells_NNS expressing_VBG the_DT entry/fusion_NN receptors_NNS ._SENT We_PP found_VBD that_IN deletions_NNS overlapping_VBG either_RB or_CC both_DT of_IN the_DT HVEM_NP contact_NN regions_NNS ,_, in_IN either_DT HSV-1_NP or_CC HSV-2_NP gD_NNS ,_, severely_RB reduced_VBN cell_NN fusion_NN and_CC binding_JJ activity_NN with_IN all_DT of_IN the_DT human_JJ and_CC mouse_NN receptors_NNS except_IN nectin-1_NN ._SENT Amino_NN acid_NN substitutions_NNS described_VBD previously_RB for_IN HSV-1_NP (_( L25P_NP ,_, Q27P_NP ,_, and_CC Q27R_NP )_) were_VBD individually_RB introduced_VBN into_IN HSV-2_JJ gD_NNS and_CC ,_, for_IN both_DT serotypes_NNS ,_, were_VBD found_VBN to_TO be_VB without_IN effect_NN on_IN cell_NN fusion_NN and_CC the_DT binding_JJ activity_NN for_IN nectin-1_NN ._SENT Each_DT of_IN these_DT three_CD substitutions_NNS in_IN HSV-1_JJ gD_NNS enhanced_JJ fusion_NN with_IN cells_NNS expressing_VBG human_JJ nectin-2_NN (_( ordinarily_RB low_JJ for_IN wild-type_JJ HSV-1_NP gD_NNS )_) ,_, but_CC the_DT same_JJ substitutions_NNS in_IN HSV-2_NP gD_NNS were_VBD without_IN effect_NN on_IN the_DT already_RB high_JJ level_NN of_IN cell_NN fusion_NN observed_VBD with_IN the_DT wild-type_NN protein_NN ._SENT The_DT Q27P_NP or_CC Q27R_NP substitution_NN in_IN either_DT HSV-1_NP and_CC HSV-2_NP gD_NNS ,_, but_CC not_RB the_DT L25P_NP substitution_NN ,_, significantly_RB reduced_VBN cell_NN fusion_NN and_CC binding_JJ activity_NN for_IN both_DT human_JJ and_CC mouse_NN HVEM_NN ._SENT Each_DT of_IN the_DT three_CD substitutions_NNS in_IN HSV-1_JJ gD_NNS ,_, as_RB well_RB as_IN the_DT deletions_NNS mentioned_VBN above_IN ,_, reduced_VBN fusion_NN with_IN cells_NNS bearing_VBG 3-O-sulfated_JJ heparan_NN sulfate_NN ._SENT Thus_RB ,_, the_DT N_NP terminus_NN of_IN HSV-1_NP or_CC HSV-2_NP gD_NN is_VBZ not_RB necessary_JJ for_IN functional_JJ interactions_NNS with_IN nectin-1_NN but_CC is_VBZ necessary_JJ for_IN all_DT of_IN the_DT other_JJ receptors_NNS tested_VBN here_RB ._SENT The_DT sequence_NN of_IN the_DT N_NP terminus_NN determines_VBZ whether_IN nectin-2_JJ or_CC 3-O-sulfated_JJ heparan_JJ sulfate_NN ,_, as_RB well_RB as_IN HVEM_NP ,_, can_MD serve_VB as_IN entry/fusion_NN receptors_NNS ._SENT Human_JJ herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) and_CC HSV-2_NP ,_, porcine_JJ pseudorabies_NP virus_NN (_( PRV_NP )_) ,_, and_CC bovine_JJ herpesvirus_NN type_NN 1_CD (_( BHV-1_NP )_) are_VBP members_NNS of_IN the_DT alphaherpesvirus_NN subfamily_NN and_CC have_VBP similar_JJ viral_JJ and_CC cellular_JJ requirements_NNS for_IN entry_NN into_IN cells_NNS ._SENT Initial_JJ attachment_NN is_VBZ usually_RB mediated_VBN by_IN interaction_NN of_IN virion_NN envelope_NN glycoprotein_NN C_NP (_( gC_NN )_) and/or_CC gB_NN with_IN cell_NN surface_NN heparan_NN sulfate_NN ._SENT The_DT subsequent_JJ interaction_NN of_IN virion_NN gD_NNS with_IN one_CD of_IN its_PP$ receptors_NNS triggers_VBZ the_DT penetration_NN of_IN virus_NN ,_, which_WDT occurs_VBZ by_IN fusion_NN of_IN the_DT viral_JJ envelope_NN with_IN a_DT cell_NN membrane_NN ,_, and_CC requires_VBZ four_CD viral_JJ glycoproteins_NNS ,_, gB_NN ,_, gD_NNS ,_, gH_NNS ,_, and_CC gL_NN ._SENT HSV-induced_JJ cell_NN fusion_NN requires_VBZ the_DT same_JJ four_CD viral_JJ glycoproteins_NNS --_: -gB_NN ,_, gD_NNS ,_, gH_NNS ,_, and_CC gL_NN --_: -as_NNS well_RB as_IN a_DT gD_JJ receptor_NN ._SENT Transfection_NN of_IN cells_NNS with_IN plasmids_NNS expressing_VBG gB_NN ,_, gD_NNS ,_, gH_NNS ,_, and_CC gL_NN is_VBZ sufficient_JJ ,_, in_IN the_DT absence_NN of_IN virus_NN infection_NN ,_, to_TO induce_VB fusion_NN with_IN target_NN cells_NNS expressing_VBG HSV_NP entry_NN receptors_NNS ._SENT Three_CD classes_NNS of_IN cell_NN surface_NN molecules_NNS can_MD serve_VB as_IN entry/fusion_NN receptors_NNS for_IN HSV-1_NP or_CC HSV-2_NP ._SENT These_DT include_VBP herpesvirus_NN entry_NN mediator_NN (_( HVEM_NP )_) ,_, a_DT member_NN of_IN the_DT tumor_NN necrosis_NN factor_NN receptor_NN family_NN ;_: nectin-1_JJ and_CC nectin-2_JJ ,_, two_CD members_NNS of_IN the_DT immunoglobulin_NN superfamily_NN ;_: and_CC specific_JJ sites_NNS in_IN heparan_JJ sulfate_NN generated_VBN by_IN the_DT action_NN of_IN certain_JJ isoforms_NNS of_IN 3-O-sulfotransferase_JJ (_( 3-OST_JJ )_) ._SENT Human_JJ and_CC ,_, as_RB shown_VBN here_RB ,_, mouse_NN forms_NNS of_IN HVEM_NP can_MD mediate_VB entry_NN of_IN both_DT HSV-1_NP and_CC HSV-2_NP ,_, but_CC not_RB PRV_NP or_CC BHV-1_NP ._SENT Human_JJ and_CC mouse_NN forms_NNS of_IN nectin-1_NN can_MD serve_VB as_IN entry_NN receptors_NNS for_IN HSV-1_NP ,_, HSV-2_NP ,_, PRV_NP ,_, and_CC BHV-1_NP ,_, whereas_IN human_NN and_CC mouse_NN forms_NNS of_IN nectin-2_NN have_VBP limited_VBN entry_NN activity_NN ._SENT Human_JJ nectin-2_NN can_MD mediate_VB the_DT entry_NN of_IN HSV-2_NP and_CC PRV_NP but_CC has_VBZ considerably_RB less_JJR activity_NN with_IN HSV-1_NP ,_, unless_IN there_EX is_VBZ an_DT amino_NN acid_NN substitution_NN at_IN position_NN 25_CD or_CC 27_CD of_IN gD_NNS ._SENT Mouse_NN nectin-2_NN can_MD mediate_VB the_DT entry_NN of_IN PRV_NP but_CC not_RB BHV-1_NP or_CC HSV_NP strains_NNS ._SENT Specific_JJ sites_NNS in_IN heparan_JJ sulfate_NN generated_VBN by_IN human_JJ or_CC mouse_NN 3-O-sulfotranferases_NNS ,_, 3-OST-3A_JJ or_CC 3-OST-3B_JJ ,_, can_MD serve_VB as_IN entry_NN receptors_NNS for_IN HSV-1_NP ._SENT X-ray_NN structures_NNS of_IN a_DT truncated_JJ form_NN of_IN HSV-1_JJ gD_NNS ,_, alone_RB and_CC in_IN complex_NN with_IN truncated_JJ HVEM_NP ,_, were_VBD recently_RB determined_VBN ._SENT A_DT portion_NN of_IN the_DT gD_NN ectodomain_NN forms_VBZ an_DT immunoglobulin_NN fold_NN in_IN both_DT structures_NNS ,_, with_IN N-terminal_JJ and_CC C-terminal_JJ extensions_NNS ._SENT The_DT N-terminal_JJ extension_NN forms_VBZ a_DT hairpin_NN in_IN the_DT complex_NN with_IN HVEM_NP but_CC is_VBZ disordered_VBN in_IN the_DT crystal_NN of_IN gD_NNS alone_RB ._SENT The_DT interface_NN between_IN gD_NN and_CC HVEM_NP involves_VBZ only_RB two_CD short_JJ segments_NNS of_IN gD_NNS (_( amino_NN acids_NNS 7_CD to_TO 15_CD and_CC 24_CD to_TO 32_CD )_) in_IN the_DT N-terminal_JJ hairpin_NN ._SENT These_DT observations_NNS suggest_VBP that_IN the_DT N_NP terminus_NN of_IN gD_NN is_VBZ conformationally_RB flexible_JJ and_CC that_IN gD_NNS may_MD have_VB different_JJ conformations_NNS upon_IN binding_VBG different_JJ receptors_NNS ._SENT A_DT single_JJ amino_NN acid_NN substitution_NN at_IN position_NN 27_CD (_( Q27P_NP or_CC Q27R_NP )_) in_IN HSV-1_JJ gD_NN prevents_VBZ binding_VBG to_TO HVEM_NP and_CC entry_NN via_IN HVEM_NP ,_, a_DT finding_VBG consistent_JJ with_IN the_DT contact_NN sites_NNS identified_VBN in_IN the_DT X-ray_NN structure_NN ,_, but_CC has_VBZ no_DT negative_JJ effect_NN on_IN binding_VBG to_TO nectin-1_NN or_CC entry_NN via_IN nectin-1_NN ._SENT Intriguingly_RB ,_, these_DT substitutions_NNS confer_VBP the_DT ability_NN to_TO use_VB nectin-2_NN as_IN an_DT entry/fusion_NN receptor_NN ._SENT The_DT inability_NN of_IN PRV_NP and_CC BHV-1_NP to_TO use_VB HVEM_NP as_IN an_DT entry/fusion_NN receptor_NN can_MD be_VB explained_VBN by_IN significant_JJ divergence_NN of_IN PRV_NP and_CC BHV-1_NP gD_NN sequences_NNS from_IN HSV-1_NP and_CC HSV-2_NP gD_NNS in_IN the_DT N-terminal_JJ domain_NN that_WDT has_VBZ the_DT contact_NN sites_NNS for_IN HVEM_NP ._SENT However_RB ,_, there_EX must_MD be_VB structural_JJ conservation_NN elsewhere_RB in_IN the_DT proteins_NNS to_TO explain_VB the_DT fact_NN that_IN all_DT four_CD viruses_NNS can_MD use_VB nectin-1_JJ as_IN an_DT entry/fusion_NN receptor_NN ._SENT These_DT observations_NNS imply_VBP that_IN the_DT interfaces_NNS of_IN gD_NNS with_IN different_JJ receptors_NNS are_VBP different_JJ ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP investigated_VBD whether_IN the_DT N-terminal_JJ domains_NNS of_IN HSV-1_NP and_CC HSV-2_NP gD_NNS were_VBD critical_JJ for_IN functional_JJ interactions_NNS with_IN each_DT of_IN the_DT known_VBN human_NN and_CC mouse_NN entry/fusion_NN receptors_NNS ._SENT We_PP identified_VBD amino_NN acid_NN substitutions_NNS or_CC deletions_NNS that_IN significantly_RB altered_VBN or_CC reduced_VBN physical_JJ and_CC functional_JJ interactions_NNS with_IN HVEM_NP ,_, nectin-2_NN and_CC 3-O-sulfated_JJ heparan_JJ sulfate_NN but_CC were_VBD without_IN effect_NN on_IN interactions_NNS with_IN nectin-1_NN ._SENT Cells_NNS ._SENT |_SYM Chinese_JJ hamster_NN ovary_NN (_( CHO-K1_JJ )_) cells_NNS were_VBD provided_VBN by_IN J._NP Esko_NP (_( University_NP of_IN California_NP ,_, San_NP Diego_NP )_) ._SENT CHO-IEbeta8_JJ cells_NNS ,_, obtained_VBN by_IN the_DT stable_JJ transfection_NN of_IN CHO-K1_JJ cells_NNS with_IN pMLP01_JJ ,_, express_VB the_DT Escherichia_NP coli_NNS lacZ_NN gene_NN under_IN control_NN of_IN the_DT HSV-1_NP ICP4_NP promoter_NN ._SENT CHO-K1_JJ cells_NNS stably_RB expressing_VBG human_JJ HVEM_NP ,_, nectin-1_JJ ,_, or_CC nectin-2_NN were_VBD originally_RB designated_VBN CHO-HveA35_NP ,_, CHO-Prr1_NP ,_, or_CC CHO-Prr2_NP ,_, respectively_RB ._SENT Here_RB they_PP are_VBP called_VBN CHO-HVEM_NP ,_, CHO-nectin-1_NP ,_, and_CC CHO-nectin-2_NP ,_, respectively_RB ._SENT All_DT cells_NNS were_VBD grown_VBN in_IN Ham_NP F12_NP medium_NN with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN ._SENT Plasmids_NNS ._SENT |_SYM Plasmids_NNS encoding_VBG HSV_NP entry_NN receptors_NNS included_VBD pcDNA3-based_JJ constructs_NNS as_RB follows_VBZ :_: pBEC10_NN expressing_VBG human_JJ HVEM_NP ,_, pBG38_NN expressing_VBG human_JJ nectin-1_NN ,_, human_JJ 3-OST-3B_NN whose_WP$ expression_NN generates_VBZ HSV-1_JJ entry_NN receptors_NNS ,_, and_CC pDS106_JJ expressing_VBG mouse_NN HVEM_NN and_CC pCR13_JJ expressing_VBG mouse_NN nectin-1_NN ._SENT HSV-1_NP and_CC HSV-2_NP gD_NN mutants_NNS were_VBD generated_VBN by_IN using_VBG the_DT QuickChange_NP site-directed_JJ mutagenesis_NN kit_NN (_( Strategene_NP )_) ._SENT HSV-1_JJ gD_NN mutants_NNS were_VBD generated_VBN by_IN using_VBG pAZT3_NN ,_, which_WDT contains_VBZ the_DT open_JJ reading_NN frame_NN (_( ORF_NP )_) of_IN HSV-1(KOS)_NP gD_NNS in_IN pUC19_NN (_( nucleotides_NNS 138419_CD to_TO 139603_CD cloned_VBN between_IN the_DT EcoRI_NP and_CC SphI_NP restriction_NN sites_NNS )_) ._SENT HSV-2_JJ gD_NN mutants_NNS were_VBD generated_VBN by_IN using_VBG pMY1_NN ,_, constructed_VBN by_IN subcloning_VBG the_DT EcoRI-KpnI_NP fragment_NN ,_, containing_VBG the_DT HSV-2(333)_NP ORF_NP ,_, from_IN pAZD2_NN into_IN pUC19_NN ._SENT pMY1_NN contains_VBZ nucleotides_NNS 141016_CD to_TO 142197_CD cloned_VBN between_IN the_DT EcoRI_NP and_CC KpnI_NP sites_NNS in_IN pUC19_NN ._SENT Nucleotide_NN numbers_NNS are_VBP from_IN the_DT published_VBN sequences_NNS of_IN the_DT HSV-1_JJ genome_NN (_( NC_001806_NP )_) and_CC the_DT HSV-2(HG52)_NP genome_NN (_( NC_001798_NP )_) ._SENT Plasmids_NNS expressing_VBG the_DT various_JJ forms_NNS of_IN gD_NNS and_CC mutants_NNS were_VBD generated_VBN by_IN subcloning_VBG the_DT EcoRI-SphI_NP fragment_NN (_( for_IN HSV-1_JJ gD_NNS )_) or_CC the_DT EcoRI-KpnI_NP fragment_NN (_( for_IN HSV-2_NP gD_NNS )_) from_IN the_DT pUC19-based_JJ plasmids_NNS into_IN pCAGGS/MCS_NNS ._SENT Plasmids_NNS expressing_VBG soluble_JJ gD:Fc_NN hybrids_NNS were_VBD constructed_VBN to_TO contain_VB the_DT first_JJ 320_CD codons_NNS of_IN HSV-1(KOS)_NP gD_NNS (_( excluding_VBG the_DT signal_NN sequence_NN )_) or_CC the_DT first_JJ 319_CD codons_NNS of_IN HSV-2(333)_NP gD_NNS (_( wild-type_NN or_CC mutant_JJ forms_NNS )_) fused_VBN to_TO the_DT C_NP terminus_NN of_IN the_DT rabbit_NN immunoglobulin_NN G_NP (_( IgG_NP )_) heavy_JJ chain_NN ._SENT The_DT appropriate_JJ region_NN of_IN each_DT gD_NN gene_NN was_VBD amplified_VBN by_IN PCR_NP with_IN primers_NNS that_WDT added_VBD an_DT upstream_JJ HindIII_NP site_NN and_CC a_DT downstream_JJ KpnI_NP site_NN and_CC the_DT pUC19-based_JJ plasmids_NNS as_IN templates_NNS ._SENT The_DT PCR_NP products_NNS were_VBD cloned_VBN into_IN pDM19_NN ,_, which_WDT is_VBZ a_DT pcDNA3-based_JJ plasmid_NN and_CC contains_VBZ the_DT cytomegalovirus_NN promoter_NN upstream_RB of_IN a_DT HindIII_NP site_NN and_CC 231_CD codons_NNS of_IN the_DT rabbit_NN IgG_NP heavy-chain_NN gene_NN downstream_JJ of_IN a_DT KpnI_NP site_NN ._SENT For_IN HSV-1_JJ gD:Fc_NN plasmids_NNS ,_, the_DT primer_NN pairs_NNS consisted_VBN of_IN 5'-GGACCAAAGCTTGAATTCCTTTTGTGTGGT-3_NP '_POS and_CC 5'-TCGAGCTCGGTACCCGGCGATCAGGCCCAT-3_NP '_POS ._SENT For_IN HSV-2_NP gD:Fc_NN plasmids_NNS ,_, the_DT primer_NN pairs_NNS consisted_VBN of_IN 5'-GGACCAAAGCTTGAATTCGTGTGCATCGCG-3_NP '_POS and_CC 5'-TCGAGCTCGGTACCCGATGATCAGGCCCGG-3_NP '_POS ._SENT The_DT introduced_VBN restriction_NN endonuclease_NN recognition_NN sequences_NNS are_VBP shown_VBN in_IN boldface_JJ ._SENT All_DT plasmids_NNS used_VBN in_IN the_DT present_JJ study_NN were_VBD verified_VBN by_IN DNA_NP sequencing_NP through_IN the_DT gD_NN genes_NNS and_CC are_VBP listed_VBN in_IN Table_NP ._SENT Viruses_NNS and_CC viral_JJ entry_NN assay_NN ._SENT |_SYM HSV-1(F)_NP ,_, HSV-1(U10)_NP ,_, HSV-1(KOS)_NP ,_, HSV-1(KOS)Rid1_NP ,_, HSV-1(KOS)tk12_NP ,_, and_CC HSV-1(KOS)Rid1/tk12_NP were_VBD described_VBN previously_RB ._SENT Entry_NN assays_NNS were_VBD based_VBN on_IN quantitation_NN of_IN beta-galactosidase_NN expressed_VBN from_IN the_DT viral_JJ genome_NN or_CC expressed_VBN in_IN CHO-IEbeta8_NP cells_NNS as_IN a_DT result_NN of_IN viral_JJ entry_NN ._SENT CHO-IEbeta8_JJ cells_NNS are_VBP induced_VBN to_TO express_VB beta-galactosidase_NN upon_IN viral_JJ entry_NN and_CC delivery_NN of_IN the_DT HSV-1_NP transactivator_NN VP16_NP into_IN cells_NNS ._SENT At_IN low-input_NN multiplicities_NNS of_IN infection_NN ,_, the_DT beta-galactosidase_NN activity_NN detected_VBN from_IN the_DT reporter_NN gene_NN in_IN virus_NN or_CC cell_NN is_VBZ proportional_JJ to_TO the_DT number_NN of_IN cells_NNS infected_JJ ;_: when_WRB all_DT cells_NNS are_VBP infected_VBN ,_, the_DT enzyme_NN activity_NN reaches_VBZ a_DT plateau_NN (_( L._NP Kwon_NP and_CC P._NP G._NP Spear_NP ,_, unpublished_JJ data_NNS )_) ._SENT Parental_JJ CHO-K1_NP ,_, CHO-HVEM_NP ,_, or_CC CHO-nectin-1_JJ cells_NNS were_VBD plated_VBN in_IN 96-well_NP plates_VBZ (_( ca_MD ._SENT 5_CD x_SYM 104_CD cells_NNS per_IN well_RB )_) ._SENT The_DT next_JJ day_NN ,_, the_DT cells_NNS were_VBD incubated_VBN with_IN serial_JJ dilutions_NNS of_IN the_DT beta-galactosidase_NN reporter_NN viruses_NNS ,_, HSV-1(KOS)tk12_NP or_CC HSV-1(KOS)Rid1/tk12_NP ,_, at_IN 37C_JJ for_IN 6_CD h._NN Alternatively_RB ,_, CHO-IEbeta8_NP cells_NNS were_VBD transfected_VBN with_IN plasmids_NNS expressing_VBG human_JJ HVEM_NP (_( pBEC10_NN )_) ,_, human_JJ nectin-1_NN (_( pBG38_NN )_) ,_, mouse_NN HVEM_NP (_( pDS106_NN )_) ,_, or_CC mouse_NN nectin-1_NN (_( pCR13_NN )_) for_IN 6_CD h_NN and_CC then_RB plated_VBN in_IN 96-well_NN plates_NNS overnight_JJ ._SENT Cells_NNS were_VBD incubated_VBN with_IN serial_JJ dilutions_NNS of_IN HSV-1(KOS)_NP ,_, HSV-1(KOS)Rid1_NP ,_, HSV-1(F)_NP ,_, or_CC HSV-1(U10)_NP at_IN 37C_JJ for_IN 6_CD h._NN The_DT cells_NNS were_VBD then_RB washed_VBN ,_, permeabilized_VBN ,_, and_CC incubated_VBD with_IN the_DT beta-galactosidase_NN substrate_NN ,_, O-nitrophenyl-beta-d-galactopyranoside_NP (_( ONPG_NP ;_: Sigma_NP )_) ._SENT The_DT reaction_NN was_VBD monitored_VBN at_IN 410_CD nm_NN in_IN a_DT Spectra_NP Max_NP 250_CD enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) reader_NN ._SENT Preparation_NN of_IN soluble_JJ gD:Fc_NN fusion_NN proteins_NNS ._SENT |_SYM Soluble_JJ gD:Fc_NN fusion_NN proteins_NNS were_VBD produced_VBN as_IN described_VBN previously_RB with_IN modification_NN ._SENT Briefly_RB subconfluent_JJ CHO-K1_JJ cells_NNS in_IN six-well_NN plates_NNS were_VBD transfected_VBN with_IN gD:Fc-expressing_VBG plasmids_NNS for_IN 6_CD h_NN by_IN using_VBG Lipofectamine_NP (_( Invitrogen_NP )_) in_IN serum-free_JJ medium_NN and_CC changed_VBN into_IN medium_NN containing_VBG 10_CD %_NN fetal_JJ bovine_JJ serum_NN overnight_RB ._SENT Cells_NNS were_VBD then_RB washed_VBN and_CC incubated_VBN with_IN serum-free_JJ medium_NN ,_, and_CC supernatants_NNS were_VBD collected_VBN 48_CD h_NN later_RBR ._SENT The_DT culture_NN supernatants_NNS were_VBD clarified_VBN by_IN low-speed_NN centrifugation_NN ,_, and_CC the_DT concentrations_NNS of_IN gD:Fc_NN proteins_NNS were_VBD determined_VBN by_IN ELISA_NP by_IN using_VBG an_DT anti-rabbit_JJ Fc_NP detection_NN system_NN and_CC rabbit_NN IgG_NP for_IN the_DT standard_JJ curve_NN ._SENT Receptor-binding_NN assay_NN ._SENT |_SYM The_DT receptor-binding_NN assay_NN was_VBD described_VBN previously_RB ._SENT CHO_NP cells_NNS expressing_VBG HSV-1_NP or_CC HSV-2_NP entry/fusion_NN receptors_NNS were_VBD grown_VBN on_IN coverslips_NNS and_CC incubated_VBN with_IN gD:Fc_NN at_IN 10_CD ng/ml_NNS and_CC 37C_JJ for_IN 30_CD min_NN ._SENT Cells_NNS were_VBD washed_VBN ,_, fixed_VBN with_IN methanol_NN at_IN -20C_NN for_IN 5_CD min_NN ,_, and_CC incubated_VBD with_IN Alexa_NP 488-conjugated_JJ goat_NN anti-rabbit_NN IgG_NP (_( Molecular_NP Probes_NP )_) ._SENT Binding_VBG was_VBD visualized_VBN by_IN confocal_JJ microscopy_NN ._SENT Alternatively_RB ,_, cell_NN ELISA_NP (_( CELISA_NP )_) was_VBD performed_VBN ._SENT Cells_NNS grown_VBN on_IN 96-well_NN plates_NNS were_VBD incubated_VBN with_IN serial_JJ dilutions_NNS of_IN gD:Fc_NN for_IN 30_CD to_TO 60_CD min_NN at_IN 37C_JJ ._SENT Cells_NNS were_VBD washed_VBN and_CC fixed_VBN with_IN 2_CD %_NN formaldehyde_NN and_CC 0.2_CD %_NN glutaraldehyde_NN for_IN 10_CD min_NN ._SENT The_DT cells_NNS were_VBD then_RB sequentially_RB incubated_VBN with_IN biotinylated_JJ anti-rabbit_NN IgG_NP (_( Sigma_NP )_) ,_, Amdex_NP streptavidin-conjugated_JJ horseradish_NN peroxidase_NN (_( HRP_NP ;_: Amersham_NP )_) ,_, and_CC HRP_NP substrates_NNS (_( BioFx_NP Lab_NP )_) ._SENT Binding_VBG was_VBD monitored_VBN at_IN 370_CD nm_NN ._SENT Assay_NN for_IN cell_NN surface_NN expression_NN of_IN gD_NNS ._SENT |_SYM CELISA_NP was_VBD carried_VBN out_RP to_TO detect_VB cell_NN surface_NN expression_NN of_IN gD_NNS ,_, as_RB described_VBN previously_RB ._SENT Briefly_RB ,_, subconfluent_JJ CHO-K1_JJ cells_NNS in_IN six-well_NN plates_NNS were_VBD transfected_VBN with_IN pCAGGS-based_JJ plasmids_NNS expressing_VBG various_JJ forms_NNS of_IN gD_NNS ,_, along_RB with_IN gB_NN ,_, gH_NNS ,_, and_CC gL_NN for_IN 6_CD h_NN and_CC replated_JJ on_IN 96-well_NN plates_NNS overnight_JJ ._SENT The_DT cells_NNS were_VBD then_RB incubated_VBN with_IN polyclonal_JJ anti-gD_JJ rabbit_NN serum_NN (_( R7_JJ )_) at_IN 37C_JJ for_IN 30_CD min_NN ,_, fixed_VBN ,_, and_CC sequentially_RB incubated_VBN with_IN biotinylated_JJ anti-rabbit_NN IgG_NP ,_, streptavidin-conjugated_JJ HRP_NP ,_, and_CC HRP_NP substrates_NNS ._SENT Binding_VBG was_VBD monitored_VBN at_IN 370_CD nm_NN ._SENT Cell_NN fusion_NN assay_NN ._SENT |_SYM Details_NNS of_IN the_DT cell_NN fusion_NN assay_NN were_VBD described_VBN previously_RB ._SENT Effector_NN (_( CHO-K1_JJ )_) cells_NNS were_VBD transfected_VBN with_IN a_DT mixture_NN of_IN plasmids_NNS expressing_VBG HSV_NP glycoproteins_NNS (_( gB_NN ,_, gD_NNS ,_, gH_NNS ,_, and_CC gL_NN )_) and_CC T7_JJ RNA_NP polymerase_NN (_( pCAGT7_JJ )_) ._SENT Plasmids_NNS expressing_VBG the_DT HSV-1(KOS)_NP glycoproteins_NNS were_VBD described_VBN elsewhere_RB :_: pPEP98_NP (_( gB_NN )_) ,_, pPEP100_JJ (_( gH_NNS )_) ,_, and_CC pPEP101_JJ (_( gL_NN )_) ._SENT Plasmids_NNS expressing_VBG the_DT HSV-2(333)_NP glycoproteins_NNS have_VBP also_RB been_VBN described_VBN :_: pAZB2_NP (_( gB_NN )_) ,_, pAZD2_JJ (_( gD_NNS )_) ,_, pAZH2_JJ (_( gH_NNS )_) ,_, and_CC pAZL2_JJ (_( gL_NN )_) ._SENT The_DT target_NN cells_NNS were_VBD CHO-HVEM_NP ,_, CHO-nectin-1_NP ,_, CHO-nectin-2_NP ,_, or_CC CHO-K1_JJ cells_NNS transiently_RB transfected_VBN with_IN human_JJ 3-OST-3B_JJ ,_, mouse_NN HVEM_NN or_CC mouse_NN nectin-1_NN ._SENT All_DT target_NN cells_NNS were_VBD transfected_VBN or_CC cotransfected_VBN with_IN a_DT plasmid_NN expressing_VBG luciferase_NN under_IN control_NN of_IN the_DT T7_JJ promoter_NN (_( pT7EMLuc_NN )_) ._SENT Effector_NN and_CC target_NN cells_NNS were_VBD subsequently_RB detached_VBN and_CC mixed_VBN in_IN a_DT 1:1_CD ratio_NN and_CC replated_JJ for_IN 18_CD h._JJ Luciferase_NP activity_NN was_VBD quantitated_VBN by_IN a_DT luciferase_NN reporter_NN assay_NN system_NN (_( Promega_NP )_) by_IN using_VBG a_DT TD-20/20_NP luminometer_NN (_( Turner_NP Designs_NPS )_) ._SENT Immunofluorescence_NN and_CC microscopy_NN ._SENT |_SYM Indirect_NN immunofluorescence_NN was_VBD carried_VBN out_RP as_RB described_VBN previously_RB ._SENT The_DT primary_JJ antibodies_NNS used_VBN were_VBD mouse_NN monoclonal_NN anti-nectin-1_JJ antibody_NN R1.302_NN and_CC rabbit_NN polyclonal_JJ anti-HVEM_NN antibody_NN R11874_NP ._SENT The_DT secondary_JJ antibodies_NNS used_VBN were_VBD Alexa_NP 488-conjuated_JJ goat_NN anti-mouse_NN IgG_NP and_CC Alexa_NP 488-labeled_JJ anti-rabbit_NN IgG_NP ._SENT Immunofluroscence_NN observations_NNS were_VBD made_VBN with_IN a_DT Zeiss_NP LSM_NP 510_CD confocal_JJ microscope_NN equipped_VBN with_IN a_DT x100_NN ,_, 1.4_CD numerical_JJ aperture_NN oil_NN immersion_NN objective_NN lens_NN ._SENT Orthogonal_JJ sections_NNS were_VBD made_VBN in_IN a_DT z_NN stack_NN of_IN 30_CD images_NNS (_( 0.6-mum_NN interval_NN )_) according_VBG to_TO the_DT LSM_NP 510_CD operating_VBG manual_NN ._SENT Effect_NN of_IN substitutions_NNS at_IN position_NN 25_CD in_IN HSV-1_JJ gD_NNS on_IN HVEM-mediated_JJ entry_NN ._SENT |_SYM Viral_NP mutants_NNS with_IN amino_NN acid_NN substitutions_NNS in_IN the_DT N-terminal_JJ region_NN of_IN HSV-1_JJ gD_NNS have_VBP been_VBN described_VBN previously_RB ._SENT As_RB mentioned_VBN above_RB ,_, Rid_NP mutants_NNS of_IN HSV-1(KOS)_NP have_VBP substitutions_NNS at_IN position_NN 27_CD (_( Q27P_NP or_CC Q27R_NP )_) that_IN significantly_RB reduce_VB their_PP$ ability_NN to_TO use_VB human_JJ HVEM_NN as_IN an_DT entry_NN receptor_NN and_CC enhance_VB their_PP$ ability_NN to_TO use_VB human_JJ nectin-2_NN ._SENT The_DT U10_NP mutant_NN of_IN HSV-1(F)_NP has_VBZ a_DT substitution_NN at_IN position_NN 25_CD (_( L25P_NP )_) and_CC has_VBZ enhanced_VBN ability_NN to_TO use_VB human_JJ nectin-2_NN as_IN an_DT entry_NN receptor_NN ._SENT Results_NNS have_VBP not_RB previously_RB been_VBN reported_VBN for_IN effects_NNS of_IN the_DT U10_NP mutation_NN on_IN viral_JJ entry_NN via_IN human_JJ HVEM_NP or_CC for_IN effects_NNS of_IN any_DT of_IN these_DT mutations_NNS on_IN entry_NN via_IN mouse_NN HVEM_NP ._SENT Therefore_RB ,_, we_PP inoculated_VBD CHO_NP cells_NNS expressing_VBG human_JJ or_CC mouse_NN HVEM_NN with_IN the_DT Rid_NP and_CC U10_NP mutants_NNS and_CC HSV-1_JJ parental_JJ strains_NNS and_CC assessed_VBD the_DT efficiency_NN of_IN viral_JJ entry_NN by_IN quantitation_NN of_IN beta-galactosidase_NN ,_, which_WDT was_VBD expressed_VBN from_IN a_DT reporter_NN gene_NN under_IN control_NN of_IN the_DT immediate-early_JJ HSV-1_NP ICP4_NP promoter_NN ,_, either_CC in_IN the_DT viral_JJ genome_NN or_CC in_IN the_DT cell_NN ._SENT Because_IN the_DT inoculated_VBN cells_NNS were_VBD permeabilized_VBN for_IN beta-galactosidase_NN quantitation_NN at_IN 6_CD h_NN after_IN the_DT addition_NN of_IN virus_NN ,_, viruses_NNS that_WDT failed_VBD to_TO enter_VB the_DT cells_NNS or_CC entered_VBN at_IN a_DT very_RB slow_JJ rate_NN would_MD score_VB as_RB impaired_VBN for_IN entry_NN ._SENT As_IN positive_JJ controls_NNS ,_, CHO_NP cells_NNS expressing_VBG human_JJ or_CC mouse_NN nectin-1_NN were_VBD also_RB inoculated_VBN ._SENT As_IN negative_JJ controls_NNS ,_, CHO-K1_JJ cells_NNS were_VBD inoculated_VBN ._SENT The_DT results_NNS presented_VBN in_IN Fig._NN show_NN ,_, first_RB ,_, that_IN the_DT human_NN and_CC mouse_NN forms_NNS of_IN nectin-1_JJ or_CC HVEM_NP were_VBD similar_JJ in_IN their_PP$ ability_NN ,_, or_CC failure_NN ,_, to_TO mediate_VB entry_NN of_IN the_DT mutant_NN and_CC wild-type_NN forms_NNS of_IN HSV-1_NP ._SENT Second_RB ,_, whereas_IN the_DT Rid_NP mutation_NN (_( Q27P_NP )_) eliminated_VBD the_DT ability_NN of_IN the_DT mutant_NN to_TO infect_VB cells_NNS expressing_VBG human_JJ or_CC mouse_NN HVEM_NP ,_, the_DT U10_NP mutation_NN (_( L25P_NP )_) had_VBD a_DT lesser_JJR effect_NN but_CC reduced_VBD the_DT efficiency_NN of_IN infection_NN for_IN cells_NNS expressing_VBG either_DT form_NN of_IN HVEM_NP ._SENT At_IN least_JJS 10_CD times_NNS more_RBR of_IN the_DT U10_NP mutant_NN than_IN the_DT wild-type_JJ parental_JJ strain_NN F_NN was_VBD required_VBN to_TO achieve_VB similar_JJ levels_NNS of_IN entry_NN ._SENT Third_JJ ,_, the_DT Rid_NP mutant_NN appeared_VBD to_TO infect_VB nectin-1-expressing_VBG cells_NNS less_RBR efficiently_RB than_IN did_VBD HSV-1(KOS)_NP ,_, whereas_IN there_EX was_VBD little_JJ difference_NN between_IN the_DT U10_NP mutant_NN and_CC HSV-1(F)_NP in_IN this_DT regard_NN ._SENT Finally_RB ,_, some_DT differences_NNS between_IN the_DT parental_JJ strains_NNS are_VBP evident_JJ ._SENT Lower_JJR input_NN multiplicities_NNS of_IN HSV-1(F)_NP than_IN HSV-1(KOS)_NP achieved_VBD similar_JJ levels_NNS of_IN viral_JJ entry_NN on_IN the_DT nectin-1-expressing_NN and_CC HVEM-expressing_NN cells_NNS ._SENT Also_RB ,_, infection_NN of_IN the_DT control_NN CHO_NP cells_NNS could_MD be_VB detected_VBN at_IN high_JJ input_NN concentrations_NNS of_IN HSV-1(F)_NP but_CC not_RB at_IN all_DT for_IN HSV-1(KOS_NP )_) ._SENT This_DT latter_JJ difference_NN with_IN respect_NN to_TO CHO_NP cells_NNS was_VBD reported_VBN previously_RB and_CC indicates_VBZ that_IN there_EX is_VBZ a_DT weak_JJ endogenous_JJ strain-dependent_JJ CHO_NP entry_NN receptor_NN for_IN HSV-1_NP ._SENT It_PP should_MD be_VB noted_VBN that_IN the_DT amino_NN acid_NN sequences_NNS of_IN the_DT gD_JJ genes_NNS of_IN these_DT two_CD strains_NNS are_VBP identical_JJ in_IN the_DT ectodomain_NN and_CC differ_VB by_IN only_RB two_CD amino_NN acids_NNS in_IN the_DT membrane-proximal_JJ region_NN of_IN the_DT cytoplasmic_JJ tail_NN ._SENT The_DT explanation_NN for_IN the_DT observed_JJ differences_NNS between_IN HSV-1(KOS)_NP and_CC HSV-1(F)_NP in_IN the_DT efficiency_NN of_IN viral_JJ entry_NN or_CC early_JJ events_NNS leading_VBG to_TO gene_NN expression_NN could_MD lie_VB in_IN these_DT differences_NNS or_CC in_IN differences_NNS in_IN other_JJ genes_NNS ._SENT We_PP conclude_VBP that_IN mouse_NN and_CC human_JJ HVEM_NP are_VBP indistinguishable_JJ in_IN their_PP$ entry_NN activities_NNS ,_, at_IN least_JJS for_IN the_DT viral_JJ strains_NNS analyzed_VBN in_IN Fig._NN ,_, despite_IN our_PP$ previous_JJ mentions_NNS of_IN unpublished_JJ and_CC preliminary_JJ findings_NNS that_IN HSV-1(KOS)Rid_NP mutants_NNS could_MD infect_VB cells_NNS via_IN mouse_NN HVEM_NP ._SENT We_PP also_RB conclude_VBP that_IN the_DT Q27P_NP substitution_NN has_VBZ a_DT more_RBR profound_JJ effect_NN on_IN entry_NN via_IN HVEM_NN than_IN does_VBZ the_DT L25P_NP substitution_NN ,_, although_IN the_DT fact_NN that_IN the_DT mutant_JJ viral_JJ strains_NNS are_VBP not_RB isogenic_JJ could_MD have_VB influenced_VBN the_DT results_NNS ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP have_VBP assessed_VBN the_DT effects_NNS of_IN both_DT of_IN these_DT mutations_NNS ,_, as_RB well_RB as_IN others_NNS ,_, in_IN the_DT HSV-1(KOS)_NP and_CC HSV-2(333)_NP genetic_JJ backgrounds_NNS ._SENT Mutations_NNS in_IN the_DT N-terminal_JJ region_NN of_IN HSV-2_NP gD_NNS have_VBP not_RB yet_RB been_VBN described_VBN ._SENT Amino_NN acid_NN substitutions_NNS and_CC deletions_NNS were_VBD introduced_VBN into_IN the_DT HSV-1_NP and_CC HSV-2_NP gD_NN genes_NNS ._SENT The_DT altered_JJ forms_NNS of_IN gD_NNS were_VBD expressed_VBN as_IN soluble_JJ hybrid_JJ proteins_NNS in_IN which_WDT the_DT ectodomain_NN of_IN gD_NNS was_VBD fused_VBN to_TO the_DT Fc_NP region_NN of_IN rabbit_NN IgG_NP ._SENT The_DT hybrids_NNS were_VBD used_VBN to_TO assess_VB the_DT effects_NNS of_IN the_DT mutations_NNS on_IN ability_NN of_IN gD_NNS to_TO bind_VB to_TO cell_NN surface_NN nectin-1_NN and_CC HVEM_NP ._SENT Binding_VBG to_TO the_DT other_JJ receptors_NNS studied_VBN here_RB ,_, nectin-2_JJ and_CC 3-O-sulfated_JJ heparan_JJ sulfate_NN ,_, could_MD not_RB be_VB assessed_VBN in_IN this_DT way_NN ,_, probably_RB because_IN of_IN lower_JJR affinities_NNS of_IN binding_VBG ._SENT The_DT full-length_JJ mutant_JJ forms_NNS of_IN gD_NNS were_VBD also_RB expressed_VBN in_IN CHO_NP cells_NNS ,_, along_RB with_IN gB_NN ,_, gH_NNS ,_, and_CC gL_NN ,_, to_TO quantitate_VB effects_NNS of_IN the_DT mutations_NNS on_IN ability_NN of_IN the_DT glycoprotein-expressing_JJ cells_NNS (_( effector_NN cells_NNS )_) to_TO induce_VB fusion_NN with_IN cells_NNS expressing_VBG the_DT various_JJ receptors_NNS (_( target_NN cells_NNS )_) ._SENT This_DT cell_NN fusion_NN assay_NN provided_VBD a_DT convenient_JJ way_NN to_TO test_VB the_DT functional_JJ activity_NN of_IN multiple_JJ gD_NN mutants_NNS and_CC yielded_VBN results_NNS likely_JJ to_TO be_VB predictive_JJ of_IN the_DT effects_NNS of_IN the_DT mutations_NNS on_IN viral_JJ entry_NN ._SENT Effects_NNS of_IN mutations_NNS in_IN the_DT N_NP termini_NNS of_IN HSV-1_NP and_CC HSV-2_NP gDs_NNS on_IN binding_VBG of_IN gD:Fcs_NNS to_TO nectin-1_JJ and_CC HVEM_NP ._SENT |_SYM Binding_NP of_IN the_DT mutant_JJ forms_NNS of_IN gD:Fcs_NNS to_TO entry_NN receptors_NNS was_VBD assessed_VBN qualitatively_RB by_IN immunofluorescence_NN and_CC quantitatively_RB by_IN measuring_VBG the_DT amounts_NNS bound_VBN to_TO intact_JJ cells_NNS in_IN monolayer_NN (_( CELISA_NP )_) ._SENT Figure_NN illustrates_VBZ differences_NNS in_IN the_DT cellular_JJ localization_NN of_IN human_JJ HVEM_NP and_CC nectin-1_JJ in_IN stably_RB expressing_VBG CHO_NP cells_NNS ,_, as_RB determined_VBN by_IN antibody_NN binding_NN and_CC by_IN the_DT binding_NN of_IN wild-type_NN forms_NNS of_IN HSV-1_NP or_CC HSV-2_NP gD:Fcs_NNS ._SENT As_IN previously_RB shown_VBN ,_, antibodies_NNS specific_JJ for_IN nectin-1_NN localized_VBN to_TO regions_NNS where_WRB two_CD cells_NNS come_VBN in_IN contact_NN ,_, reflecting_VBG the_DT ability_NN of_IN this_DT cell_NN adhesion_NN molecule_NN to_TO engage_VB in_IN homophilic_JJ trans-interactions_NNS between_IN cells_NNS ._SENT Nectin-2_NP exhibits_VBZ the_DT same_JJ cellular_JJ localization_NN ._SENT Antibodies_NNS to_TO HVEM_NP ,_, on_IN the_DT other_JJ hand_NN ,_, were_VBD distributed_VBN all_RB over_IN the_DT cell_NN surface_NN ,_, at_IN least_JJS all_RB over_IN the_DT surface_NN not_RB in_IN contact_NN with_IN the_DT substrate_NN ._SENT The_DT other_JJ panels_NNS of_IN Fig._NN show_VBP that_IN HSV-1_JJ gD:Fc_NN (_( panels_NNS G_NP and_CC H_NP )_) and_CC HSV-2_NP gD:Fc_NN (_( panels_NNS I_PP and_CC J_NP )_) bound_VBN to_TO the_DT cells_NNS in_IN patterns_NNS similar_JJ to_TO those_DT of_IN the_DT anti-nectin-1_NN and_CC anti-HVEM_NN antibodies_NNS ._SENT CHO_NP cells_NNS expressing_VBG mouse_NN nectin-1_NN or_CC HVEM_NP bound_VBD both_DT HSV-1_NP and_CC HSV-2_NP gD:Fcs_NNS in_IN patterns_NNS indistinguishable_JJ from_IN those_DT shown_VBN in_IN Fig._NN for_IN the_DT human_JJ receptors_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Control_NP CHO_NP cells_NNS devoid_JJ of_IN exogenous_JJ receptors_NNS failed_VBD to_TO bind_VB the_DT anti-nectin-1_JJ antibodies_NNS ,_, anti-HVEM_NN antibodies_NNS or_CC gD:Fcs_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT We_PP have_VBP noted_VBN previously_RB the_DT colocalization_NN of_IN anti-nectin-1_JJ antibodies_NNS and_CC gD:Fcs_NNS at_IN cell_NN contact_NN sites_NNS and_CC the_DT enhancement_NN of_IN gD:Fc_NN binding_NN when_WRB cell_NN adhesions_NNS are_VBP disrupted_VBN ,_, indicating_VBG that_IN homophilic_JJ trans-interactions_NNS of_IN nectin-1_NN can_MD reduce_VB ,_, but_CC not_RB prevent_VB ,_, gD:Fc_NN binding_NN ._SENT In_IN the_DT first_JJ 37_CD amino_NN acids_NNS of_IN HSV-1_JJ gD_NNS ,_, which_WDT includes_VBZ the_DT N-terminal_JJ hairpin_NN present_NN in_IN the_DT gD-HVEM_NN complex_NN ,_, there_EX are_VBP only_RB two_CD amino_NN acid_NN differences_NNS from_IN HSV-2_JJ gD_NNS (_( A7P_NP and_CC D21N_NP )_) ,_, as_RB shown_VBN in_IN Fig._NN ._SENT Thus_RB ,_, the_DT amino_NN acid_NN substitutions_NNS previously_RB characterized_VBN in_IN HSV-1_NP could_MD also_RB be_VB investigated_VBN in_IN HSV-2_NP ._SENT The_DT mutations_NNS introduced_VBN into_IN HSV-1(KOS)_NP and_CC HSV-2(333)_NP gDs_NNS and_CC gD:Fcs_NNS are_VBP listed_VBN in_IN Table_NP ,_, along_RB with_IN the_DT names_NNS of_IN the_DT relevant_JJ plasmids_NNS ._SENT These_DT mutations_NNS included_VBD the_DT U10_NP (_( L25P_NP )_) and_CC Rid_NP (_( Q27P_NP and_CC Q27R_NP )_) substitutions_NNS and_CC combinations_NNS of_IN both_DT ._SENT They_PP also_RB included_VBD a_DT triple_JJ substitution_NN (_( L25P/Q27R/T230I_NP )_) found_VBD in_IN HSV-1(ANG)_NP ,_, which_WDT results_VBZ in_IN a_DT phenotype_NN similar_JJ to_TO that_DT of_IN the_DT Rid_NP mutants_NNS ._SENT In_IN addition_NN ,_, various_JJ deletions_NNS encompassing_VBG the_DT regions_NNS in_IN gD_NNS that_WDT make_VBP contact_NN with_IN HVEM_NP were_VBD made_VBN ._SENT The_DT wild-type_NN and_CC mutant_JJ forms_NNS of_IN the_DT gD:Fcs_NNS were_VBD tested_VBN by_IN immunofluorescence_NN for_IN their_PP$ ability_NN to_TO bind_VB to_TO cells_NNS expressing_VBG nectin-1_JJ or_CC HVEM_NP ._SENT The_DT results_NNS (_( not_RB shown_VBN )_) can_MD be_VB summarized_VBN briefly_RB ._SENT All_DT of_IN the_DT HSV-1_NP and_CC HSV-2_NP mutant_JJ gD:Fcs_NNS bound_VBN to_TO cells_NNS expressing_VBG either_CC the_DT human_JJ or_CC mouse_NN forms_NNS of_IN nectin-1_NN ,_, in_IN a_DT pattern_NN similar_JJ to_TO that_WDT observed_VBD for_IN the_DT wild-type_NN gD:Fcs_NNS ._SENT On_IN the_DT other_JJ hand_NN ,_, all_RB of_IN the_DT mutant_JJ gD:Fcs_NNS ,_, except_IN for_IN L25P_NP ,_, failed_VBD to_TO bind_VB to_TO cells_NNS expressing_VBG either_CC the_DT human_JJ or_CC mouse_NN forms_NNS of_IN HVEM_NP ._SENT Both_CC the_DT HSV-1_NP and_CC HSV-2_NP L25P_NP mutant_JJ forms_NNS of_IN gD:Fc_NN bound_VBN to_TO cells_NNS expressing_VBG either_DT HVEM_NP or_CC nectin-1_JJ in_IN patterns_NNS indistinguishable_JJ from_IN wild-type_NN ._SENT To_TO quantify_VB the_DT binding_NN to_TO nectin-1_JJ and_CC HVEM_NP ,_, serial_JJ dilutions_NNS of_IN the_DT wild-type_NN and_CC mutant_JJ gD:Fcs_NNS were_VBD incubated_VBN with_IN cells_NNS expressing_VBG human_JJ or_CC mouse_NN nectin-1_NN or_CC HVEM_NP in_IN the_DT CELISA_NP assay_NN ._SENT Figure_NN shows_VBZ the_DT results_NNS obtained_VBN with_IN the_DT HSV-1_NP and_CC HSV-2_NP substitution_NN mutants_NNS ,_, and_CC Fig._NN shows_VBZ the_DT results_NNS obtained_VBN with_IN the_DT deletion_NN mutants_NNS ._SENT All_DT of_IN the_DT mutants_NNS bound_VBN to_TO human_JJ or_CC mouse_NN nectin-1_NN with_IN certain_JJ quantitative_JJ differences_NNS observed_VBD ._SENT Specifically_RB ,_, all_DT of_IN the_DT HSV-1_JJ substitution_NN mutants_NNS bound_VBN more_RBR efficiently_RB than_IN wild-type_NN gD:Fc_NN to_TO nectin-1_JJ ,_, human_JJ or_CC mouse_NN ,_, and_CC all_DT of_IN the_DT HSV-2_NP substitution_NN mutants_NNS ,_, except_IN for_IN L25P_NP ,_, also_RB bound_VBN with_IN greater_JJR efficiency_NN (_( based_VBN on_IN equivalent_JJ binding_NN at_IN input_NN concentrations_NNS 1/3_CD to_TO 1/10_CD that_IN of_IN wild-type_NN gD:Fc_NN )_) ._SENT The_DT HSV-2_NP L25P_NP mutant_NN was_VBD indistinguishable_JJ from_IN wild-type_JJ HSV-2_NP gD:Fc_NN in_IN its_PP$ binding_NN to_TO nectin-1_NN ._SENT All_DT of_IN the_DT deletion_NN mutants_NNS bound_VBN to_TO nectin-1_JJ as_IN efficiently_RB as_RB did_VBD wild-type_NN forms_NNS of_IN the_DT gD:Fcs_NNS ,_, except_IN for_IN HSV-2_NP deletion_NN 7-21_CD ,_, which_WDT required_VBD up_RP to_TO 10_CD times_NNS higher_JJR concentrations_NNS for_IN binding_JJ equivalent_NN to_TO that_WDT of_IN wild-type_NN gD:Fc_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, none_NN of_IN the_DT substitution_NN or_CC deletion_NN mutants_NNS bound_VBN to_TO either_DT form_NN of_IN HVEM_NP ,_, except_IN for_IN HSV-1_NP and_CC HSV-2_NP L25P_NP ,_, a_DT finding_VBG consistent_JJ with_IN the_DT immunofluorescence_NN results_NNS (_( not_RB shown_VBN )_) ._SENT Effects_NNS of_IN mutations_NNS in_IN the_DT N_NP termini_NNS of_IN HSV-1_NP and_CC HSV-2_NP gDs_NNS on_IN cell_NN fusion_NN ._SENT |_SYM It_PP was_VBD previously_RB shown_VBN that_IN cells_NNS expressing_VBG the_DT Q27P_NP mutant_NN of_IN HSV-1_JJ gD_NNS ,_, along_RB with_IN wild-type_NN forms_NNS of_IN HSV-1_JJ gB_NN ,_, gH_NNS ,_, and_CC gL_NN ,_, had_VBD significantly_RB reduced_VBN ability_NN to_TO induce_VB fusion_NN with_IN target_NN cells_NNS expressing_VBG HVEM_NP ,_, enhanced_JJ ability_NN to_TO induce_VB fusion_NN with_IN cells_NNS expressing_VBG nectin-2_NN ,_, and_CC unchanged_JJ ability_NN to_TO induce_VB fusion_NN with_IN cells_NNS expressing_VBG nectin-1_JJ ,_, a_DT finding_VBG consistent_JJ with_IN the_DT entry_NN phenotypes_NNS of_IN Rid_NP mutant_JJ viruses_NNS ._SENT None_NN of_IN the_DT other_JJ gD_NN mutations_NNS described_VBD here_RB have_VB been_VBN tested_VBN previously_RB for_IN their_PP$ effects_NNS on_IN cell_NN fusion_NN ._SENT CHO_NP cells_NNS were_VBD transfected_VBN with_IN each_DT wild-type_NN or_CC mutant_JJ form_NN of_IN HSV-1_NP or_CC HSV-2_NP gD_NNS ,_, along_RB with_IN wild-type_NN forms_NNS of_IN HSV-1_NP or_CC HSV-2_NP gB_NP ,_, gH_NN ,_, and_CC gL_NN in_IN homologous_JJ combinations_NNS ._SENT These_DT effector_NN cell_NN populations_NNS were_VBD then_RB divided_VBN ,_, and_CC portions_NNS were_VBD replated_VBN in_IN 96-well_NN dishes_NNS for_IN CELISA_NP assays_VBZ to_TO quantitate_VB the_DT cell_NN surface_NN expression_NN of_IN gD_NN ,_, while_IN the_DT remainder_NN of_IN each_DT population_NN was_VBD mixed_VBN with_IN target_NN cells_NNS expressing_VBG each_DT of_IN the_DT known_VBN HSV-1_NP or_CC HSV-2_NP fusion/entry_NN receptors_NNS for_IN cell_NN fusion_NN assays_NNS ._SENT Cell_NN fusion_NN was_VBD quantitated_VBN by_IN measuring_VBG the_DT activity_NN of_IN luciferase_NN ,_, which_WDT can_MD be_VB expressed_VBN only_RB after_IN effector_NN and_CC target_NN cells_NNS have_VBP fused_VBN ._SENT The_DT results_NNS are_VBP presented_VBN in_IN Fig._NN for_IN the_DT substitution_NN mutants_NNS and_CC in_IN Fig._NN for_IN the_DT deletion_NN mutants_NNS ._SENT Panels_NNS A_NP and_CC C_NP in_IN both_DT figures_NNS show_VBP that_IN the_DT mutant_NN and_CC wild-type_NN forms_NNS of_IN gD_NNS were_VBD expressed_VBN at_IN equivalent_JJ levels_NNS on_IN the_DT surfaces_NNS of_IN the_DT effector_NN cells_NNS ._SENT The_DT cell_NN fusion_NN results_NNS (_( panels_NNS B_NP and_CC D_NP in_IN Fig._NN and_CC )_) demonstrate_VB the_DT following_NN ._SENT (_( i_NP )_) All_DT of_IN the_DT amino_NN acid_NN substitutions_NNS in_IN HSV-1_JJ gD_NNS ,_, except_IN L25P_NP ,_, reduced_VBD cell_NN fusion_NN with_IN human_JJ HVEM_NP to_TO ca_MD ._SENT 5_CD %_NN of_IN the_DT wild-type_NN level_NN and_CC with_IN mouse_NN HVEM_NP to_TO 10_CD to_TO 20_CD %_NN of_IN the_DT wild-type_NN level_NN ._SENT Similar_JJ results_NNS were_VBD obtained_VBN with_IN the_DT HSV-2_NP substitution_NN mutants_NNS except_IN that_WDT the_DT reduction_NN in_IN levels_NNS of_IN cell_NN fusion_NN was_VBD not_RB quite_RB so_RB pronounced_VBN ._SENT (_( ii_NP )_) All_DT amino_NN acid_NN substitutions_NNS at_IN positions_NNS 25_CD and/or_CC 27_CD in_IN HSV-1_JJ gD_NNS significantly_RB increased_VBD cell_NN fusion_NN activity_NN with_IN target_NN cells_NNS expressing_VBG human_JJ nectin-2_NN and_CC reduced_VBN fusion_NN with_IN cells_NNS expressing_VBG 3-OST-3B_JJ ._SENT These_DT mutations_NNS in_IN HSV-2_NP gD_NNS were_VBD without_IN effect_NN on_IN the_DT already_RB significant_JJ level_NN of_IN cell_NN fusion_NN observed_VBN with_IN wild-type_JJ HSV-2_NP gD_NN and_CC human_JJ nectin-2_NN ._SENT (_( iii_NP )_) All_DT of_IN the_DT amino_NN acid_NN substitutions_NNS in_IN HSV-2_NP gD_NNS reduced_VBD cell_NN fusion_NN with_IN parental_JJ CHO-K1_JJ cells_NNS to_TO 20_CD to_TO 35_CD %_NN of_IN the_DT wild-type_NN level_NN ._SENT (_( iv_NN )_) All_DT of_IN the_DT deletions_NNS in_IN HSV-1_NP or_CC HSV-2_NP gD_NNS significantly_RB reduced_VBN cell_NN fusion_NN with_IN cells_NNS expressing_VBG any_DT of_IN the_DT receptors_NNS except_IN nectin-1_NN ._SENT Values_NNS close_JJ to_TO the_DT background_NN values_NNS found_VBN in_IN the_DT absence_NN of_IN gD_NNS were_VBD noted_VBN for_IN some_DT of_IN the_DT deletions_NNS ,_, particularly_RB for_IN those_DT missing_VBG at_IN least_JJS amino_NN acids_NNS 24_CD to_TO 32_CD and_CC for_IN all_DT target_NN cells_NNS except_IN those_DT expressing_VBG nectin-1_NN and_CC those_DT expressing_VBG human_JJ nectin-2_NN or_CC 3-OST-3B_NN when_WRB tested_VBN with_IN the_DT HSV-1_JJ mutants_NNS ._SENT (_( v_NN )_) None_NN of_IN the_DT amino_NN acid_NN substitutions_NNS or_CC deletions_NNS had_VBD any_DT appreciable_JJ effect_NN on_IN cell_NN fusion_NN when_WRB the_DT target_NN cells_NNS expressed_VBD either_DT human_NN or_CC mouse_NN nectin-1_NN ._SENT Figure_NN demonstrated_VBD that_DT deletion_NN 7-21_CD in_IN HSV-2_JJ gD_NNS ,_, but_CC not_RB in_IN HSV-1_JJ gD_NNS ,_, reduced_VBD the_DT efficiency_NN of_IN binding_VBG of_IN the_DT soluble_JJ gD:Fc_NN to_TO nectin-1_JJ ;_: however_RB ,_, neither_DT mutation_NN had_VBD any_DT discernible_JJ effect_NN on_IN fusion_NN with_IN nectin-1-expressing_VBG cells_NNS ._SENT It_PP is_VBZ possible_JJ that_IN (_( i_NP )_) the_DT fusion_NN assay_NN cannot_MD discriminate_VB among_IN different_JJ levels_NNS of_IN activity_NN above_IN a_DT certain_JJ threshold_NN ,_, (_( ii_NNS )_) the_DT different_JJ forms_NNS of_IN gD_NNS used_VBN in_IN the_DT binding_NN and_CC fusion_NN assays_NNS were_VBD affected_VBN differently_RB by_IN the_DT deletion_NN in_IN the_DT case_NN of_IN HSV-2_NP (_( both_CC forms_NNS were_VBD checked_VBN for_IN presence_NN of_IN the_DT appropriate_JJ deletion_NN and_CC absence_NN of_IN unwanted_JJ mutations_NNS )_) ,_, or_CC (_( iii_NNS )_) a_DT wide_JJ range_NN of_IN binding_JJ affinities_NNS can_MD be_VB associated_VBN with_IN the_DT same_JJ level_NN of_IN fusion_NN activity_NN ._SENT As_IN we_PP noted_VBD previously_RB ,_, mutations_NNS in_IN nectin-1_NN that_WDT reduced_VBD gD_JJ binding_NN did_VBD not_RB necessarily_RB affect_VB HSV_NP entry_NN activity_NN ._SENT A_DT deletion_NN of_IN 7_CD to_TO 21_CD amino_NN acids_NNS in_IN HSV-1(F)_NP gD_NNS was_VBD previously_RB characterized_VBN ._SENT Virus_NN expressing_VBG this_DT mutant_JJ gD_NN appeared_VBD indistinguishable_JJ from_IN wild-type_NP HSV-1(F)_NP for_IN plaque_NN formation_NN on_IN Vero_NP cells_NNS and_CC replication_NN in_IN a_DT human_JJ cell_NN line_NN ,_, suggesting_VBG that_IN the_DT receptor_NN used_VBN by_IN this_DT mutant_NN might_MD have_VB been_VBN nectin-1_JJ ._SENT We_PP can_MD conclude_VB that_IN the_DT N-terminal_JJ region_NN of_IN either_DT HSV-1_NP or_CC HSV-2_NP gD_NN is_VBZ dispensable_JJ for_IN the_DT binding_NN of_IN gD_NNS to_TO nectin-1_JJ and_CC for_IN fusion_NN with_IN cells_NNS expressing_VBG nectin-1_JJ ,_, whereas_IN this_DT region_NN is_VBZ required_VBN for_IN full_JJ activity_NN with_IN all_DT of_IN the_DT other_JJ receptors_NNS tested_VBD ._SENT Moreover_RB ,_, the_DT amino_NN acid_NN sequence_NN within_IN the_DT N_NP terminus_NN governs_VBZ the_DT level_NN of_IN activity_NN with_IN each_DT of_IN these_DT receptors_NNS ._SENT We_PP were_VBD surprised_VBN to_TO find_VB that_IN all_DT but_CC one_CD of_IN the_DT mutations_NNS described_VBD here_RB had_VBN effects_NNS on_IN functional_JJ interactions_NNS of_IN both_DT HSV-1_NP and_CC HSV-2_NP gDs_NNS with_IN all_DT of_IN the_DT known_JJ HSV_NP fusion/entry_NN receptors_NNS except_IN nectin-1_NN ._SENT The_DT results_NNS with_IN HVEM_NP were_VBD largely_RB predictable_JJ ,_, but_CC the_DT other_JJ results_NNS were_VBD not_RB ,_, for_IN the_DT reasons_NNS given_VBN below_IN ._SENT The_DT importance_NN of_IN amino_NN acid_NN Q27_JJ in_IN the_DT HSV-1_NP gD-HVEM_NN interaction_NN was_VBD evident_JJ from_IN the_DT crystal_NN structure_NN of_IN the_DT HVEM-gD_JJ complex_NN ._SENT This_DT showed_VBD that_IN Q27_NP is_VBZ part_NN of_IN a_DT short_JJ extended_JJ strand_NN that_WDT forms_VBZ hydrogen_NN bonds_NNS with_IN a_DT beta_JJ strand_NN in_IN HVEM_NP ._SENT The_DT side_NN chain_NN of_IN Q27_JJ points_NNS toward_IN an_DT alpha-helix_NN in_IN gD_NN that_WDT is_VBZ sandwiched_VBN between_IN the_DT N-terminal_JJ hairpin_NN and_CC the_DT immunoglobulin_NN fold_NN ._SENT This_DT side_NN chain_NN inserts_NNS into_IN a_DT pocket_NN too_RB small_JJ to_TO accommodate_VB an_DT arginine_NN residue_NN (_( as_IN in_IN Q27R_NP )_) ._SENT The_DT Q27P_NP substitution_NN would_MD be_VB expected_VBN to_TO distort_VB the_DT beta-strand_NN interaction_NN ._SENT New_JJ information_NN presented_VBD here_RB is_VBZ that_IN mutations_NNS in_IN the_DT same_JJ position_NN in_IN HSV-2_NP gD_NNS also_RB disrupted_VBN physical_JJ and_CC functional_JJ interactions_NNS with_IN HVEM_NP ._SENT It_PP is_VBZ not_RB yet_RB known_VBN how_WRB similar_JJ are_VBP the_DT structures_NNS of_IN HSV-1_NP and_CC HSV-2_NP gD_NNS ._SENT An_DT earlier_JJR study_NN performed_VBN with_IN soluble_JJ truncated_JJ forms_NNS of_IN gD_NNS (_( 306_CD amino_NN acids_NNS instead_RB of_IN 285_CD in_IN the_DT form_NN that_WDT was_VBD crystallized_VBN )_) used_VBD circular_JJ dichroism_NN to_TO estimate_VB the_DT secondary_JJ structure_NN content_NN of_IN both_DT HSV-1_NP and_CC HSV-2_NP gDs_NNS ._SENT HSV-2_NP gD_NNS exhibited_VBD properties_NNS consistent_JJ with_IN little_JJ or_CC no_DT alpha-helical_JJ content_NN compared_VBN to_TO 10_CD %_NN for_IN HSV-1_JJ gD_NNS ._SENT Also_RB ,_, the_DT beta-sheet_NN content_NN was_VBD estimated_VBN to_TO be_VB higher_JJR for_IN HSV-2_JJ gD_NNS than_IN for_IN HSV-1_JJ gD_NNS ._SENT However_RB ,_, similar_JJ or_CC different_JJ the_DT structures_NNS prove_VBP to_TO be_VB ,_, substitutions_NNS Q27P_NP or_CC Q27R_NP in_IN either_DT HSV-1_NP or_CC HSV-2_NP gD_NNS disrupt_VB interactions_NNS with_IN HVEM_NP ,_, both_DT human_NN and_CC mouse_NN ._SENT The_DT gD_JJ amino_NN acid_NN L25_NP also_RB points_VBZ toward_IN the_DT alpha-helix_NN mentioned_VBN above_RB and_CC ,_, although_IN not_RB part_NN of_IN the_DT extended_JJ strand_NN that_WDT forms_VBZ hydrogen_NN bonds_NNS with_IN the_DT beta-strand_NN in_IN HVEM_NP ,_, the_DT L25P_NP substitution_NN might_MD be_VB expected_VBN to_TO affect_VB this_DT interaction_NN ._SENT The_DT carbonyl_NN group_NN of_IN L25_NP forms_VBZ a_DT hydrogen_NN bond_NN via_IN a_DT water_NN molecule_NN with_IN the_DT hydroxyl_NN group_NN of_IN Y23_NP in_IN HVEM_NP ._SENT Despite_IN these_DT structural_JJ findings_NNS ,_, our_PP$ results_NNS show_VBP that_IN the_DT L25P_NP substitution_NN in_IN HSV-1_NP or_CC HSV-2_NP gD_NNS had_VBD little_JJ or_CC no_DT effect_NN on_IN the_DT binding_NN of_IN gD:Fc_NN to_TO HVEM_NP or_CC on_IN fusion_NN with_IN cells_NNS expressing_VBG HVEM_NP ._SENT This_DT mutation_NN in_IN HSV-1(F)U10_NP did_VBD ,_, however_RB ,_, reduce_VB the_DT efficiency_NN of_IN viral_JJ entry_NN into_IN cells_NNS expressing_VBG HVEM_NP ._SENT Perhaps_RB reduced_VBN efficiency_NN of_IN binding_VBG and_CC cell_NN fusion_NN would_MD also_RB have_VB been_VBN observed_VBN with_IN the_DT L25P_NP mutation_NN in_IN HSV-1(F)_NP gD_NNS ,_, if_IN tested_VBN as_IN the_DT HSV-1(KOS)_NP gD_NN mutants_NNS were_VBD tested_VBN ._SENT Alternatively_RB ,_, other_JJ factors_NNS may_MD influence_VB how_WRB the_DT mutant_JJ form_NN of_IN gD_JJ functions_NNS in_IN the_DT context_NN of_IN the_DT virion_NN ._SENT The_DT key_JJ point_NN ,_, however_RB ,_, is_VBZ that_IN not_RB all_RB of_IN the_DT identified_VBN contacts_NNS between_IN HVEM_NP and_CC gD_NNS are_VBP equally_RB important_JJ for_IN a_DT stable_JJ and_CC functional_JJ interaction_NN ._SENT This_DT point_NN was_VBD also_RB recently_RB documented_VBN in_IN a_DT study_NN investigating_VBG the_DT effects_NNS of_IN amino_NN acid_NN substitutions_NNS in_IN HVEM_NP on_IN interactions_NNS with_IN HSV-1_JJ gD_NNS ._SENT Interestingly_RB ,_, substitutions_NNS in_IN two_CD of_IN the_DT HVEM_NP residues_NNS (_( T35_NP and_CC V36_NP )_) that_WDT make_VBP contacts_NNS with_IN Q27_JJ reduced_VBN binding_NN to_TO HSV-1_JJ gD_NNS but_CC had_VBD little_JJ effect_NN on_IN entry_NN activity_NN of_IN the_DT altered_JJ HVEM_NP ._SENT Substitutions_NNS at_IN Y23_NP completely_RB abolished_VBD binding_VBG to_TO gD_NNS and_CC viral_JJ entry_NN activity_NN ._SENT Both_DT findings_NNS seem_VBP contradictory_JJ to_TO the_DT ones_NNS presented_VBD here_RB ,_, but_CC the_DT latter_JJ finding_NN ,_, at_IN least_JJS ,_, can_MD be_VB explained_VBN by_IN the_DT fact_NN that_IN Y23_NP makes_VBZ extensive_JJ contacts_NNS with_IN other_JJ residues_NNS of_IN gD_NNS and_CC not_RB just_RB L25_NP ._SENT The_DT most_RBS surprising_JJ findings_NNS were_VBD that_IN the_DT gD_NN mutations_NNS had_VBD such_JJ different_JJ effects_NNS on_IN functional_JJ interactions_NNS with_IN human_JJ nectin-1_NN and_CC nectin-2_NN ._SENT These_DT two_CD proteins_NNS are_VBP related_VBN in_IN sequence_NN and_CC structure_NN ,_, and_CC homologous_JJ regions_NNS of_IN the_DT two_CD receptors_NNS have_VBP been_VBN found_VBN to_TO be_VB critical_JJ for_IN HSV_NP entry_NN ._SENT Amino_NN acid_NN substitutions_NNS in_IN loops_NNS between_IN the_DT putative_JJ F_NN and_CC G_NN beta_NN strands_NNS and_CC the_DT C_NP '_POS and_CC C_NP "_'' beta_NN strands_NNS of_IN the_DT N-terminal_JJ immunoglobulin_NN folds_NNS of_IN both_DT nectin-1_JJ and_CC nectin-2_JJ have_VBP been_VBN shown_VBN to_TO reduce_VB HSV_NP entry_NN activity_NN ._SENT Also_RB ,_, other_JJ amino_NN acid_NN substitutions_NNS in_IN the_DT loop_NN between_IN the_DT C_NP '_POS and_CC C_NP "_'' beta_NN strands_NNS of_IN human_JJ and_CC mouse_NN nectin-2_NN can_MD enhance_VB or_CC confer_VB entry_NN activity_NN for_IN both_DT HSV-1_NP and_CC HSV-2_NP ._SENT It_PP seems_VBZ reasonable_JJ to_TO predict_VB that_IN contact_NN sites_NNS on_IN HSV-2_JJ gD_NNS for_IN these_DT two_CD rece_NN 